This phase II study is seeking to demonstrate that treatment with a new targeted therapy (BMS-986012) in combination with chemotherapy (carboplatin + etoposide) and immunotherapy (nivolumab) is safe, tolerable and more effective than treatment with chemotherapy and immunotherapy alone in people with newly diagnosed, extensive-stage small cell lung cancer.
This trial is treating patients with extensive-stage small cell lung cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
Commercial Sponsor
Bristol-Myers Squibb (BMS)
Summary
Eligible participants will be randomly allocated to one of two experimental arms. In Experimental Arm A, participants will receive BMS-986012 + carboplatin + etoposide + nivolumab. In Experimental Arm B, participants will receive carboplatin + etoposide + nivolumab.
Recruiting Hospitals Read More